Caisson Biotech, LLC

has developed a natural, biodegradable and adaptable drug delivery system to improve the performance of numerous types of drug compounds.

Heparinex, L.L.C.

has developed new technology to produce heparosan from the fermentation of recombinant bacteria for use in a number of applications including biomaterials, medical device coatings and dermal fillers.

Hyalose, L.L.C.

has developed technologies to produce preferred sizes of hyaluronic acid from 1) the fermentation of recombinant bacteria and 2) chemoenzymatic synthesis.

Pure MHC, LLC

is a subsidiary of Pure Protein, L.L.C., that offers breakthrough HLA-based therapeutic target discovery and validation with further drug and assay development applications.  

Pure Transplant

has developed a unique method to produce soluble HLA protein from human cell lines for application in HLA-based assay platform design as well as drug target discovery and bio-therapeutic development.

Selenium, Ltd.

has developed a catalytic shield that prevents harmful biofilms from forming on any surface that can be used to end cavities, desalinate water, create anti-microbial plastic, and more.